Loading clinical trials...
Loading clinical trials...
A Multi-Center, Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Phase II Study of 2 Oral Dose Groups of AZD7325, With a Lorazepam Arm, in Subjects With Generalized Anxiety Disorder (GAD)
The purpose of this research study is to determine whether AstraZeneca's drug AZD7325 is safe and effective in the treatment of generalized anxiety disorder.
Age
18 - 65 years
Sex
ALL
Healthy Volunteers
No
Research Site
Mesa, Arizona, United States
Research Site
Little Rock, Arkansas, United States
Research Site
Carson, California, United States
Research Site
Escondido, California, United States
Research Site
Glendale, California, United States
Research Site
Irvine, California, United States
Research Site
Redlands, California, United States
Research Site
Riverside, California, United States
Research Site
Sherman Oaks, California, United States
Research Site
Fort Lauderdale, Florida, United States
Start Date
December 1, 2008
Primary Completion Date
May 1, 2009
Completion Date
May 1, 2009
Last Updated
October 8, 2010
369
ACTUAL participants
AZD7325
DRUG
AZD7325
DRUG
Lorazepam
DRUG
Placebo
DRUG
Lead Sponsor
AstraZeneca
NCT07432945
NCT06661460
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT07235852